


The BSACI Registry for Immunotherapy (BRIT) is a nationwide project to improve outcomes for specialist allergy treatments. Registered consultant users send patient-specific data to BRIT that records access to allergen immunotherapy for rhinitis, venom immunotherapy and omalizumab for chronic urticaria. Since its launch in 2018, specialist centres have shown considerable engagement, but we wanted to understand how this represented allergy services across the UK. With no central database of NHS and non-NHS Allergy clinics, we attempted to use the BSACI registered clinics to estimate national coverage of BRIT data.




Method:

We compared allergy centres with BRIT registered consultant users to those advertised on the “find an allergy clinic” on the BSACI website. The latter search functionality allows clinics to self-report the use of treatments such as immunotherapy. We used this data as a denominator to explore coverage of registered BRIT users.

Results: 137 allergy clinics are listed on the BSACI website.

Brit Registry Uptake by Area as a Proportion of BSACI Clinics




- ❖ 65.7% (90/137) provided allergen immunotherapy (AIT),
 - 43% (58/90) of AIT centres had one BRIT registered consultant.
- ❖ 85%(116/137) using Omalizumab (OMA) for urticaria/angioedema
 - 47% (54/116) clinics had 1 BRIT registered consultant.


- ❖ 68% (96/137) provided venom immunotherapy (VIT)
 - 48% (46/96) providing VIT had one BRIT registered consultant.
- ❖ Six centres not providing immunotherapy had a BRIT registered consultant

- ❖ Uptake of AIT was similar between
 - adult centres 53% (17/32)
 - paediatric centres 56% (27/48).
- ❖ BRIT registration was highest in England
 - Outside Greater London 46% (46/100)
 - London 33% (8/24),
 - The devolved nations 31% (4/13)

Adult and Joint Paediatric & Adult Immunotherapy Clinics



Number of centres providing immunotherapy that have at least one BRIT registered consultant




Conclusions:

The BRIT registry is in use by about half of BSACI registered immunotherapy centres in the UK with recent increased uptake amongst adult centres. All self-reported BSACI-member centres may not have the treatment

programmes (overestimate) and since we excluded non-BSACI member centres (e.g. Dermatologists prescribing omalizumab for urticaria), the estimated national coverage on immunotherapy clinics may be inaccurate. The BSACI denominator is reliant on accurate updating of clinics in response to the annual BSACI email request and some trusts with more than one hospital providing different services. Further engagement of the BSACI membership is required to help to improve the data collection through the BRIT registry and provide real world patient outcomes.

Paediatric Immunotherapy Clinics



If you would like to find out more about BRIT please visit contact us brit@bsaci.org or come and see our stand in the exhibition hall